The Latest Breaking News from Eli Lilly

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s recent setback and…

Biogen Inc. (NASDAQ:BIIB) CEO Chris Viehbacher said a successful Alzheimer’s trial for Novo Nordisk A/S’ (NYSE:NVO) weight-loss drug wouldn’t threaten his company’s treatment but could instead open the door to combining therapies for stronger results.

A federal appeals court has revived a proposed class action accusing four major drugmakers of conspiring to restrict a government-mandated drug discount program, allegedly driving up costs for safety-net hospitals and clinics serving low-income patients.

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

While understanding so-called ‘options math’ can provide interesting context and color, the real alpha generation comes from an entirely different framework.

Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

The past week has been a rollercoaster ride for the financial markets. From President Donald Trump‘s surprising tariffs on gold to Eli Lilly’s worst day in 25 years, the week was filled with unexpected turns. Let’s dive into the top stories that shaped the week.

When it comes to investing, research is everything. But let’s be honest, it can also be time-consuming and overwhelming, especially if you have never invested...